Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Validation of the ProNephro AKITM (NGAL) in Adult ICU Patients in the ICU at Risk of Moderate to Severe Acute Kidney Injury (ALPACA)

NCT07751913 is registered in ClinicalTrials.gov with BioPorto Diagnostics as lead sponsor.

NCT NCT07751913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07751913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Validation of the ProNephro AKITM (NGAL) in Adult ICU Patients in the ICU at Risk of Moderate to Severe Acute Kidney Injury (ALPACA)
Lead sponsor
BioPorto Diagnostics
Phase
Observational
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
May 31, 2028
Enrollment
800 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury